返回 
加入收藏
PCI术前强化辛伐他汀治疗对急性冠脉综合征患者术后相关指标的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | PCI术前强化辛伐他汀治疗对急性冠脉综合征患者术后相关指标的影响 |
| TITLE： | |
| 摘要： | 目的：探讨经皮冠状动脉介入治疗（PCI）术前强化辛伐他汀治疗对急性冠脉综合征患者术后相关指标的影响。方法：106例急性冠脉综合征患者随机分为观察组（53例）和对照组（53例）。两组患者PCI术后均口服阿司匹林肠溶片100 mg，每日1次+氯吡格雷片75 mg，每日1次，持续4周；观察组患者于术前15 d每日晚饭前加服辛伐他汀片20 mg。观察两组患者术前和术后6个月总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、超敏C反应蛋白（hs-CRP）、白细胞介素6（IL-6）、IL-18、左室射血分数（LVEF）、冠状动脉再狭窄发生情况及不良反应发生情况。结果：两组患者术前和术后6个月TG、TC、LDL-C和HDL-C水平比较，差异均无统计学意义（P＞0.05）。术前，两组患者hs-CRP、IL-6、IL-18和LVEF水平比较，差异均无统计学意义（P＞0.05）。术后6个月，两组患者hs-CRP、IL-6、IL-18和LVEF水平均显著高于同组治疗前，但观察组hs-CRP、IL-6和IL-18均显著低于对照组，LVEF显著高于对照组，差异均有统计学意义（P＜0.05）。观察组患者冠状动脉再狭窄发生率显著低于对照组，差异有统计学意义（P＜0.05）。两组患者治疗期间均未见明显不良反应发生。结论：PCI术前强化辛伐他汀治疗，可有效降低急性冠脉综合征患者术后的心血管炎症反应程度，预防冠状动脉血栓再形成，降低术后冠状动脉再狭窄发生率，改善患者预后，且不增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To investigate the effects of simvastatin intensive treatment on the Postoperative Related Indexes of patients with acute coronary syndrome（ACS） underwent percutaneous coronary intervention（PCI）. METHODS： 106 patients with were included in the study and randomly divided into observation group （53 cases） and control group （53 cases）. Both groups were given aspirin 100 mg，qd+clopidogrel 75 mg，qd before PCI for 4 weeks； observation group was additionally given Simvastatin tablet orally 20 mg before supper 15 d before surgery. TC， TG， LDL-C， HDL-C， hs-CRP， IL-6 and IL-18 levels， LVEF， the occurrence of coronary artery restenosis were detected in 2 groups before surgery and 6 months after surgery. The occurrence of ADR was recorded during treatment. RESULTS： There was no statistical significance in the levels of TG， TC， LDL-C and HDL-C between 2 groups before surgery and 6 months after surgery （P＞0.05）. There was no statistical significance in hs-CRP， IL-18，IL-6 and LVEF levels between 2 groups before surgery（P＞0.05）. 6 months after surgery， hs-CRP， IL-6，IL-18 and LVEF levels of 2 groups were significantly higher than before treatment； hs-CRP， IL-6 and IL-18 levels of observation group were significantly lower than those of control group， and LVEF was significantly higher than control group， with statistical significance （P＜0.05）. The incidence of coronary artery restenosis in observation group was significantly lower than control group， with statistical significance （P＜0.05）. No ADR was found in 2 groups during treatment. CONCLUSIONS： Preoperative simvastatin intensive treatment can effectively reduce cardiovascular inflammation degree in patients with ACS after PCI， prevent the formation of coronary artery thrombus， and reduce the incidence of coronary artery restenosis so as to effectively improve the prognosis and don’t increase the incidence of ADR. |
| 期刊： | 2017年第28卷第12期 |
| 作者： | 张红心，吴平平，李广平，乔爱新，马红梅，赵颖 |
| AUTHORS： | ZHANG Hongxin，WU Pingping，LI Guangping，QIAO Aixin，MA Hongmei，ZHAO Ying |
| 关键字： | 辛伐他汀；急性冠脉综合征；经皮冠状动脉介入治疗；冠状动脉再狭窄 |
| KEYWORDS： | Simvastatin； Acute coronary syndrome； Percutaneous coronary intervention； Coronary artery restenosis |
| 阅读数： | 195 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
